1
|
Yu X, Matico RE, Miller R, Chauhan D, Van Schoubroeck B, Grauwen K, Suarez J, Pietrak B, Haloi N, Yin Y, Tresadern GJ, Perez-Benito L, Lindahl E, Bottelbergs A, Oehlrich D, Van Opdenbosch N, Sharma S. Structural basis for the oligomerization-facilitated NLRP3 activation. Nat Commun 2024; 15:1164. [PMID: 38326375 PMCID: PMC10850481 DOI: 10.1038/s41467-024-45396-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 01/19/2024] [Indexed: 02/09/2024] Open
Abstract
The NACHT-, leucine-rich-repeat-, and pyrin domain-containing protein 3 (NLRP3) is a critical intracellular inflammasome sensor and an important clinical target against inflammation-driven human diseases. Recent studies have elucidated its transition from a closed cage to an activated disk-like inflammasome, but the intermediate activation mechanism remains elusive. Here we report the cryo-electron microscopy structure of NLRP3, which forms an open octamer and undergoes a ~ 90° hinge rotation at the NACHT domain. Mutations on open octamer's interfaces reduce IL-1β signaling, highlighting its essential role in NLRP3 activation/inflammasome assembly. The centrosomal NIMA-related kinase 7 (NEK7) disrupts large NLRP3 oligomers and forms NEK7/NLRP3 monomers/dimers which is a critical step preceding the assembly of the disk-like inflammasome. These data demonstrate an oligomeric cooperative activation of NLRP3 and provide insight into its inflammasome assembly mechanism.
Collapse
Affiliation(s)
- Xiaodi Yu
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA.
| | - Rosalie E Matico
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA
| | - Robyn Miller
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA
| | - Dhruv Chauhan
- Johnson & Johnson Innovation Medicine, J&J Interventional Oncology, Beerse, Belgium
| | | | - Karolien Grauwen
- Johnson & Johnson Innovation Medicine, J&J Interventional Oncology, Beerse, Belgium
| | - Javier Suarez
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA
| | - Beth Pietrak
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA
| | - Nandan Haloi
- Department of Applied Physics, Swedish e-Science Research Center, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Yanting Yin
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA
| | | | - Laura Perez-Benito
- Johnson & Johnson Innovation Medicine, Discovery Sciences, Beerse, Belgium
| | - Erik Lindahl
- Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Stockholm, Sweden
| | - Astrid Bottelbergs
- Johnson & Johnson Innovation Medicine, Discovery Sciences, Beerse, Belgium
| | - Daniel Oehlrich
- Johnson & Johnson Innovation Medicine, Discovery Sciences, Beerse, Belgium
| | - Nina Van Opdenbosch
- Johnson & Johnson Innovation Medicine, J&J Interventional Oncology, Beerse, Belgium
| | - Sujata Sharma
- Johnson & Johnson Innovation Medicine, Spring House, PA, 19044, USA
| |
Collapse
|
2
|
Matico RE, Yu X, Miller R, Somani S, Ricketts MD, Kumar N, Steele RA, Medley Q, Berger S, Faustin B, Sharma S. Structural basis of the human NAIP/NLRC4 inflammasome assembly and pathogen sensing. Nat Struct Mol Biol 2024; 31:82-91. [PMID: 38177670 PMCID: PMC10803261 DOI: 10.1038/s41594-023-01143-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 09/28/2023] [Indexed: 01/06/2024]
Abstract
The NLR family caspase activation and recruitment domain-containing 4 (NLRC4) inflammasome is a critical cytosolic innate immune machine formed upon the direct sensing of bacterial infection and in response to cell stress during sterile chronic inflammation. Despite its major role in instigating the subsequent host immune response, a more complete understanding of the molecular events in the formation of the NLRC4 inflammasome in humans is lacking. Here we identify Bacillus thailandensis type III secretion system needle protein (Needle) as a potent trigger of the human NLR family apoptosis inhibitory protein (NAIP)/NLRC4 inflammasome complex formation and determine its structural features by cryogenic electron microscopy. We also provide a detailed understanding of how type III secretion system pathogen components are sensed by human NAIP to form a cascade of NLRC4 protomer through a critical lasso-like motif, a 'lock-key' activation model and large structural rearrangement, ultimately forming the full human NLRC4 inflammasome. These results shed light on key regulatory mechanisms specific to the NLRC4 inflammasome assembly, and the innate immune modalities of pathogen sensing in humans.
Collapse
Affiliation(s)
- Rosalie E Matico
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - Xiaodi Yu
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA.
| | - Robyn Miller
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - Sandeep Somani
- In Silico Discovery Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - M Daniel Ricketts
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - Nikit Kumar
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - Ruth A Steele
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - Quintus Medley
- Discovery Immunology, Johnson & Johnson Innovative Medicine, Cambridge, MA, USA
| | - Scott Berger
- Discovery Immunology, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| | - Benjamin Faustin
- Discovery Immunology, Johnson & Johnson Innovative Medicine, San Diego, CA, USA
| | - Sujata Sharma
- Structural and Protein Sciences, Johnson & Johnson Innovative Medicine, Spring House, PA, USA
| |
Collapse
|
3
|
McDevitt PJ, Schneck JL, Diaz E, Hou W, Huddleston MJ, Matico RE, McCormick PM, Kirkpatrick RB. A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences. Protein Expr Purif 2019; 164:105455. [PMID: 31306746 DOI: 10.1016/j.pep.2019.105455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 07/09/2019] [Accepted: 07/11/2019] [Indexed: 11/15/2022]
Abstract
Wolf-Hirschhorn Syndrome Candidate 1 (WHSC1; also known as NSD2) is a SET domain-containing histone lysine methyltransferase. A chromosomal translocation occurs in 15-20% of multiple myeloma patients and is associated with increased production of WHSC1 and poor clinical prognosis. To define the substrate requirements of NSD2, we established a platform for the large-scale production of recombinant polynucleosomes, based on authentic human histone proteins, expressed in E. coli, and complexed with linearized DNA. A brief survey of methyltransferases whose substrate requirements are recorded in the literature yielded expected results, lending credence to the fitness of our approach. This platform was readily 'codified' with respect to both position and extent of methylation at histone 3 lysines 18 and 36 and led to the conclusion that the most readily discernible activity of NSD2 in contact with a nucleosome substrate is dimethylation of histone 3 lysine 36. We further explored reaction mechanism, and conclude a processive, rather than distributive mechanism best describes the interaction of NSD2 with intact nucleosome substrates. The methods developed feature scale and flexibility and are suited to thorough pharmaceutical-scale drug discovery campaigns.
Collapse
Affiliation(s)
- Patrick J McDevitt
- GlaxoSmithKline Pharmaceutical Company, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA.
| | - Jessica L Schneck
- GlaxoSmithKline Pharmaceutical Company, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA
| | - Elsie Diaz
- Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, PA, USA
| | - Wangfang Hou
- GlaxoSmithKline Pharmaceutical Company, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA
| | - Michael J Huddleston
- GlaxoSmithKline Pharmaceutical Company, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA
| | - Rosalie E Matico
- Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, PA, USA
| | - Patricia M McCormick
- GlaxoSmithKline Pharmaceutical Company, 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USA
| | | |
Collapse
|
4
|
Poulin MB, Schneck JL, Matico RE, Hou W, McDevitt PJ, Holbert M, Schramm VL. Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2. J Am Chem Soc 2016; 138:6699-702. [PMID: 27183271 PMCID: PMC6702673 DOI: 10.1021/jacs.6b01612] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Nuclear receptor-binding SET domain protein 2 (NSD2) is a histone H3 lysine 36 (H3K36)-specific methyltransferase enzyme that is overexpressed in a number of cancers, including multiple myeloma. NSD2 binds to S-adenosyl-l-methionine (SAM) and nucleosome substrates to catalyze the transfer of a methyl group from SAM to the ε-amino group of histone H3K36. Equilibrium binding isotope effects and density functional theory calculations indicate that the SAM methyl group is sterically constrained in complex with NSD2, and that this steric constraint is released upon nucleosome binding. Together, these results show that nucleosome binding to NSD2 induces a significant change in the chemical environment of enzyme-bound SAM.
Collapse
Affiliation(s)
- Myles B. Poulin
- Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, United States
| | - Jessica L. Schneck
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Rosalie E. Matico
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Wangfang Hou
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Patrick J. McDevitt
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Marc Holbert
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States
| | - Vern L. Schramm
- Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, United States
| |
Collapse
|
5
|
Poulin MB, Schneck JL, Matico RE, McDevitt PJ, Huddleston MJ, Hou W, Johnson NW, Thrall SH, Meek TD, Schramm VL. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36. Proc Natl Acad Sci U S A 2016; 113:1197-201. [PMID: 26787850 PMCID: PMC4747696 DOI: 10.1073/pnas.1521036113] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Nuclear receptor SET domain containing protein 2 (NSD2) catalyzes the methylation of histone H3 lysine 36 (H3K36). It is a determinant in Wolf-Hirschhorn syndrome and is overexpressed in human multiple myeloma. Despite the relevance of NSD2 to cancer, there are no potent, selective inhibitors of this enzyme reported. Here, a combination of kinetic isotope effect measurements and quantum chemical modeling was used to provide subangstrom details of the transition state structure for NSD2 enzymatic activity. Kinetic isotope effects were measured for the methylation of isolated HeLa cell nucleosomes by NSD2. NSD2 preferentially catalyzes the dimethylation of H3K36 along with a reduced preference for H3K36 monomethylation. Primary Me-(14)C and (36)S and secondary Me-(3)H3, Me-(2)H3, 5'-(14)C, and 5'-(3)H2 kinetic isotope effects were measured for the methylation of H3K36 using specifically labeled S-adenosyl-l-methionine. The intrinsic kinetic isotope effects were used as boundary constraints for quantum mechanical calculations for the NSD2 transition state. The experimental and calculated kinetic isotope effects are consistent with an SN2 chemical mechanism with methyl transfer as the first irreversible chemical step in the reaction mechanism. The transition state is a late, asymmetric nucleophilic displacement with bond separation from the leaving group at (2.53 Å) and bond making to the attacking nucleophile (2.10 Å) advanced at the transition state. The transition state structure can be represented in a molecular electrostatic potential map to guide the design of inhibitors that mimic the transition state geometry and charge.
Collapse
Affiliation(s)
- Myles B Poulin
- Department of Biochemistry, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461
| | - Jessica L Schneck
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Rosalie E Matico
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Patrick J McDevitt
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Michael J Huddleston
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Wangfang Hou
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Neil W Johnson
- Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, PA 19426
| | - Sara H Thrall
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Thomas D Meek
- Biological Sciences, Platform Technology and Science, GlaxoSmithKline, Collegeville, PA 19426
| | - Vern L Schramm
- Department of Biochemistry, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461;
| |
Collapse
|
6
|
Ding Y, O’Keefe H, DeLorey JL, Israel DI, Messer JA, Chiu CH, Skinner SR, Matico RE, Murray-Thompson MF, Li F, Clark MA, Cuozzo JW, Arico-Muendel C, Morgan BA. Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT). ACS Med Chem Lett 2015; 6:888-93. [PMID: 26288689 DOI: 10.1021/acsmedchemlett.5b00138] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 07/07/2015] [Indexed: 12/12/2022] Open
Abstract
The aggrecan degrading metalloprotease ADAMTS-4 has been identified as a novel therapeutic target for osteoarthritis. Here, we use DNA-encoded Library Technology (ELT) to identify novel ADAMTS-4 inhibitors from a DNA-encoded triazine library by affinity selection. Structure-activity relationship studies based on the selection information led to the identification of potent and highly selective inhibitors. For example, 4-(((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-6-(((4-methylpiperazin-1-yl)methyl)amino)-1,3,5-triazin-2-yl)amino)methyl)-N-ethyl-N-(m-tolyl)benzamide has IC50 of 10 nM against ADAMTS-4, with >1000-fold selectivity over ADAMT-5, MMP-13, TACE, and ADAMTS-13. These inhibitors have no obvious zinc ligand functionality.
Collapse
Affiliation(s)
- Yun Ding
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Heather O’Keefe
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Jennifer L. DeLorey
- Tedor Pharma, Inc., 400 Highland Corporate Drive, Cumberland, Rhode Island 02864, United States
| | - David I. Israel
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Jeffrey A. Messer
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Cynthia H. Chiu
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Steven R. Skinner
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Rosalie E. Matico
- Biological
Reagent and Assay Development, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Monique F. Murray-Thompson
- Biological
Reagent and Assay Development, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Fan Li
- Tufts Healthcare Institute, 136 Harrison Avenue, Boston, Massachusetts 02111, United States
| | - Matthew A. Clark
- X-Chem, Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States
| | - John W. Cuozzo
- X-Chem, Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States
| | - Christopher Arico-Muendel
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Barry A. Morgan
- Center for Drug Discovery, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States
| |
Collapse
|
7
|
Goodman KB, Bury MJ, Cheung M, Cichy-Knight MA, Dowdell SE, Dunn AK, Lee D, Lieby JA, Moore ML, Scherzer DA, Sha D, Suarez DP, Murphy DJ, Harpel MR, Manas ES, McNulty DE, Annan RS, Matico RE, Schwartz BK, Trill JJ, Sweitzer TD, Wang DY, Keller PM, Krawiec JA, Jaye MC. Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett 2008; 19:27-30. [PMID: 19058966 DOI: 10.1016/j.bmcl.2008.11.033] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2008] [Revised: 11/06/2008] [Accepted: 11/10/2008] [Indexed: 11/30/2022]
Abstract
Endothelial lipase (EL) activity has been implicated in HDL catabolism, vascular inflammation, and atherogenesis, and inhibitors are therefore expected to be useful for the treatment of cardiovascular disease. Sulfonylfuran urea 1 was identified in a high-throughput screening campaign as a potent and non-selective EL inhibitor. A lead optimization effort was undertaken to improve potency and selectivity, and modifications leading to improved LPL selectivity were identified. Radiolabeling studies were undertaken to establish the mechanism of action for these inhibitors, which were ultimately demonstrated to be irreversible inhibitors.
Collapse
Affiliation(s)
- Krista B Goodman
- Department of Chemistry, Cardiovascular and Urogenital Center of Excellence in Drug Discovery, GlaxoSmithKline, UW2430, King of Prussia, PA 19406, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kirkpatrick RB, McDevitt PJ, Matico RE, Nwagwu S, Trulli SH, Mao J, Moore DD, Yorke AF, McLaughlin MM, Knecht KA, Elefante LC, Calamari AS, Fornwald JA, Trill JJ, Jonak ZL, Kane J, Patel PS, Sathe GM, Shatzman AR, Tapley PM, Johanson KO. A bicistronic expression system for bacterial production of authentic human interleukin-18. Protein Expr Purif 2003; 27:279-92. [PMID: 12597888 DOI: 10.1016/s1046-5928(02)00606-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Interleukin-18 (IL-18) is activated and released from immune effector cells to stimulate acquired and innate immune responses involving T and natural killer (NK) cells. The release of IL-18 from mammalian cells is linked to its proteolytic activation by caspases including interleukin 1 converting enzyme (ICE). The absence of a signal peptide sequence and the requirement for coupled activation and cellular release have presented challenges for the large-scale recombinant production of IL-18. In this study, we have explored methods for the direct production of authentic human IL-18 toward the development of a large-scale production system. Expression of mature IL-18 directly in Escherichia coli with a methionine initiating codon leads to the production of MetIL-18 that is dramatically less potent in bioassays than IL-18 produced as a pro-peptide and activated in vitro. To produce an authentic IL-18, we have devised a bicistronic expression system for the coupled transcription and translation of ProIL-18 with caspase-1 (ICE) or caspase-4 (ICE-rel II, TX, ICH-2). Mature IL-18 with an authentic N-terminus was produced and has a biological activity and potency comparable to that of in vitro processed mature IL-18. Optimization of this system for the maximal production yields can be accomplished by modulating the temperature, to affect the rate of caspase activation and to favor the accumulation of ProIL-18, prior to its proteolytic processing by activated caspase. The effect of temperature is particularly profound for the caspase-4 co-expression process, enabling optimized production levels of over 150 mg/L in shake flasks at 25 degrees C. An alternative bicistronic expression design utilizing a precise ubiquitin IL-18 fusion, processed by co-expressed ubiquitinase, was also successfully used to generate fully active IL-18, thereby demonstrating that the pro-sequence of IL-18 is not required for recombinant IL-18 production.
Collapse
Affiliation(s)
- Robert B Kirkpatrick
- Department of Gene Expression, Protein Biochemistry, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Rd, King of Prussia, PA 19406, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Kirkpatrick RB, Matico RE, McNulty DE, Strickler JE, Rosenberg M. An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 1995; 153:147-54. [PMID: 7875581 DOI: 10.1016/0378-1119(94)00756-i] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
An abundantly secreted 47-kDa glycoprotein, DS47, was purified from Drosophila melanogaster (Dm) Schneider line-2 cells, a line exhibiting macrophage-like properties. DS47 is also secreted from several Dm cell lines resembling S2 but not from lines that are morphologically distinct. A cDNA cline was isolated from an S2 cell cDNA library using oligodeoxyribonucleotide probes based on the DS47 amino acid (aa) sequence and found to encode a novel secretory glycoprotein of 452 aa. Analysis of DS47 protein production and mRNA expression during fly development indicates that both are present throughout the entire Dm life cycle, suggesting that DS47 may be important at all developmental stages. In larvae, the DS47 message is made in the fat body and by hemocytes, and secreted into the hemolymph. DS47 is related to a human cartilage glycoprotein, HC gp-39, that is secreted from cell types associated with the arthritic joint, such as synovial cells and activated macrophages. Interestingly, the HC gp-39 message is most readily detected in the human liver, an organ that is somewhat analogous to the Dm fat body. DS47 also shares homology to a mouse secretory glycoprotein, YM-1, identified in activated macrophages. These homologies extend to the chitinase gene family and include a conserved cysteine aa motif, as well as two blocks of aa within the enzymatic active site, although neither DS-47 nor HC gp-39 exhibit chitinase activity. Potential functions of this conserved protein family are discussed.
Collapse
Affiliation(s)
- R B Kirkpatrick
- Department of Gene Expression Sciences, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406
| | | | | | | | | |
Collapse
|
10
|
Morton TA, Bennett DB, Appelbaum ER, Cusimano DM, Johanson KO, Matico RE, Young PR, Doyle M, Chaiken IM. Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor. J Mol Recognit 1994; 7:47-55. [PMID: 7986567 DOI: 10.1002/jmr.300070107] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A surface plasmon resonance (SPR) biosensor was used to study the interaction of human interleukin-5 (hIL5) with its receptor. IL5 is a major growth factor in the production and activation of eosinophils. The receptor for IL5 is composed of two subunits, alpha and beta. The alpha subunit provides the specificity for IL5 and consists of an extracellular soluble domain, a single transmembrane region and a cytoplasmic tail. We expressed the soluble domain of the human IL5 receptor alpha subunit (shIL5R alpha) and human IL5 (hIL5) in Drosophila. Both hIL5 and shIL5R alpha were immobilized separately through amine groups onto the carboxylated dextran layer of sensor chips of the BIAcore (Pharmacia) SPR biosensor after N-hydroxysuccinimide/carbodiimide activation of the chip surface. Interactions were measured for the complementary macromolecule, either shIL5R alpha or hIL5, in solution. Kinetics of binding of soluble analyte to immobilized ligand were measured and from this the association rate constant, dissociation rate constant and equilibrium dissociation constant (Kd) were derived. With immobilized shIL5R alpha and soluble hIL5, the measured Kd was 2 nM. A similar value was obtained by titration calorimetry. The Kd for Drosophila expressed receptor and IL5 is higher than the values reported for proteins expressed in different systems, likely due to differences in the methods of interaction analysis used or differences in protein glycosylation. Receptor-IL5 binding was relatively pH independent between pH 6.5 and 9.5. Outside this range, the dissociation rate increased with comparatively little increase in association rate.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- T A Morton
- Department of Molecular Genetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406
| | | | | | | | | | | | | | | | | |
Collapse
|